Microbot Medical Inc.
MBOT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -5.76 | 0.00 | 0.02 | 0.00 |
| FCF Yield | -2.63% | -2.81% | -11.23% | -8.91% |
| EV / EBITDA | 479.20 | -25.23 | -8.75 | -4.72 |
| Quality | ||||
| ROIC | -4.88% | -12.16% | -10.35% | -92.43% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 50.00% |
| Cash Conversion Ratio | 1.07 | 0.74 | 1.10 | 0.50 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -49.26% | 10.56% | -70.02% | 38.46% |
| Safety | ||||
| Net Debt / EBITDA | -19.74 | 1.13 | 1.19 | 0.88 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -4,581.00 | -3,772.50 | -1,116.00 | -32.14 |